Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1636 1645 1657 1674
This examiner grants 72% of resolved cases
Kimberly Chong is a highly experienced examiner in Tech Center 1600, working within Art Unit 1635. The examiner has resolved a very large volume of 1501 cases. The allowance rate of 72.4 percent indicates a consistent and favorable approach to granting patents across this extensive caseload.
The interview lift for this examiner is 13.0 percent. This suggests that while interviews provide a benefit, the high baseline allowance rate is the primary driver of success. Interviews may be most useful for clarifying technical details rather than overcoming fundamental disagreements.
The median days to allowance is 926. This timeframe is efficient, especially considering the high volume of 1501 cases handled. The data reflects a predictable and relatively fast path to allowance for applicants working with this examiner in Art Unit 1635. This examiner demonstrates a high level of productivity and a clear path to patent issuance.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19460949 | COMPOSITIONS AND METHODS FOR PROGRAMMED DEATH LIGAND RECEPTOR (PD-L1) EXPRESSION | Non-Final OA | NOVO NORDISK A/S |
| 18345507 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of California |
| 17636481 | METHOD OF MODULATING ADIPOSITY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18272933 | ENGINEERED NUCLEIC ACIDS TARGETING LONG NONCODING RNA INVOLVED IN PATHOGENIC INFECTION | Final Rejection | President and Fellows of Harvard College |
| 18577903 | Yeast Single Nucleotide Polymorphisms for Industrially Relevant Phenotypes | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17910497 | NOVEL CAS ENZYMES AND METHODS OF PROFILING SPECIFICITY AND ACTIVITY | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18459091 | CRISPR/CAS DROPOUT SCREENING PLATFORM TO REVEAL GENETIC VULNERABILITIES ASSOCIATED WITH TAU AGGREGATION | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17814211 | ADOPTIVE CELL THERAPY USING SPHERICAL NUCLEIC ACIDS (SNAS) | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 17782976 | EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES WITH FIBROSIS | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18490131 | ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT | Non-Final OA | The Board of Regents of The University of Texas System |
| 18471280 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA | Non-Final OA | The Board of Regents of The University of Texas System |
| 17920342 | COMPOSITIONS AND METHODS FOR INTRANASAL TREATMENT WITH DOUBLE STRANDED RNA | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18164699 | NOVEL EFFICACIOUS MICRORNA-30C ANALOGS REDUCE APOLIPOPROTEIN B SECRETION IN HUMAN LIVER CELLS | Final Rejection | The United States Government as represented by the Department of Veterans Affairs |
| 18694650 | DEPLETION OF FNDC5 REDUCES CANCER INDUCED MUSCLE LOSS/CACHEXIA | Non-Final OA | The Trustees of Indiana University |
| 18705288 | NOROVIRUS VACCINE AND METHODS OF USE | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17754844 | MODULATORS OF PNPLA3 EXPRESSION | Non-Final OA | AstraZeneca AB |
| 18301089 | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17930042 | AMPHIPHILIC OLIGODEOXYNUCLEOTIDE CONJUGATES AS ADJUVANT ENHANCERS | Final Rejection | Wayne State University |
| 18279811 | DELIVERY OF ANTIBODY BY USING DUAL VIRAL VECTOR SYSTEM | Non-Final OA | Nanjing GenScript Biotech Co., Ltd. |
| 17306860 | ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE | Non-Final OA | Erasmus University Medical Center Rotterdam |
| 18700152 | METHODS AND COMPOSITIONS FOR DISRUPTING NRF2-KEAP1 PROTEIN INTERACTION BY ADAR MEDIATED RNA EDITING | Non-Final OA | KORRO BIO, INC. |
| 18281201 | COMPOSITIONS COMPRISING A VARIANT POLYPEPTIDE AND USES THEREOF | Non-Final OA | Arbor Biotechnologies, Inc. |
| 18044945 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | Final Rejection | SAPREME TECHNOLOGIES B.V. |
| 17905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | Non-Final OA | NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy